Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery

Conditions: Coronary Artery Disease, Coronary Artery Bypass Grafting, Hypoxia-Inducible Factor 1, Alpha Subunit, Prolyl-Hydroxylase Inhibitors, Myocardial Ischemia, Myocardial Infarction Postoperative

Sex: All

Ages: 45 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 80

Sponsor: Peking University First Hospital

Location: Peking University First Hospita Beijing Beijing Municipality

Summary

Myocardial injury and infarction are common after cardiac surgery and are associated with worse perioperative outcomes. Hypoxia-inducible factor (HIF) is an important metabolic regulator that protects the myocardium. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved for the treatment of anemia of chronic kidney disease; it enhances the hypoxia-protective pathway and erythropoiesis. We hypothesize that, in patients undergoing off-pump coronary artery bypass grafting (CABG), preoperative treatment with roxadustat may reduce postoperative myocardial injury or infarction. This pilot study is designed to test the feasibility of conducting a large randomized trial and to provide preliminary data on the potential effect of roxadustat on the occurrence of myocardial injury or infarction in patients undergoing off-pump CABG.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥45 years. 2. Scheduled for off-pump coronary artery bypass grafting (CABG). 3. Preoperative anemia, defined as hemoglobin \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07912801). StuddyBuddy aggregates publicly available trial information.